The role of anticoagulants, antiplatelet agents, and their reversal strategies in the management of intracerebral hemorrhage

Neurosurgical Focus

Volumn 34, Issue 5, 2013, Pages

  James, Robert F ^a   Palys, Viktoras ^b   Lomboy, Jason R ^a   Lamm, J Richard ^a   Simon, Scott D ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet; Intracerebral hemorrhage; Oral anticoagulants; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; VITAMIN K GROUP;

BRAIN HEMORRHAGE; HUMAN; METHODOLOGY; NEUROSURGERY; REVIEW; CEREBRAL HEMORRHAGE; PROCEDURES;

ANTICOAGULANTS; CEREBRAL HEMORRHAGE; HUMANS; NEUROSURGICAL PROCEDURES; PLATELET AGGREGATION INHIBITORS; VITAMIN K;

EID: 84879017028     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2013.2.FOCUS1328     Document Type: Article

References (79)

1. Akbari SH, Reynolds MR, Kadkhodayan Y, Cross DT III, Moran CJ: Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg [epub ahead of print], 2012
2. Altman R, Scazziota A, DE Lourdes Herrera M, Gonzalez C: Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 4:2022-2027, 2006
3. Beshay JE, Morgan H, Madden C, Yu W, Sarode R: Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. A review. J Neurosurg 112:307-318, 2010
4. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, et al: Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106:2550- 2554, 2002
5. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303:754-762, 2010
6. Broderick JP, Diringer MN, Hill MD, Brun NC, Mayer SA, Steiner T, et al: Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke 38:1072-1075, 2007
7. Brunton LL, Chabner BA, Knollmann BC: Goodman & Gilman's The Pharmacological Basis of Therapeutics, ed 12. New York: McGraw-Hill, 2011
8. Campbell PG, Sen A, Yadla S, Jabbour P, Jallo J: Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: a clinical review. World Neurosurg 74:279-285, 2010
9. Campbell PG, Yadla S, Sen AN, Jallo J, Jabbour P: Emergency reversal of clopidogrel in the setting of spontaneous intracerebral hemorrhage. World Neurosurg 76:100-104, 2011
10. Cantalapiedra A, Gutierrez O, Tortosa JI, Yañez M, Dueñas M, Fernandez Fontecha E, et al: Oral anticoagulant treatment: risk factors involved in 500 intracranial hemorrhages. J Thromb Thrombolysis 22:113-120, 2006
11. Caso V, Paciaroni M, Venti M, Alberti A, Palmerini F, Milia P, et al: Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. Cerebrovasc Dis 24:215-218, 2007 12. Cervera A, Amaro S, Chamorro A: Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 259:212-224, 2012
12. Cervera A, Amaro S, Chamorro A: Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 259:212-224, 2012
13. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al: Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100-2109, 2012
14. Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, et al: Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110:2361-2367, 2004
15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151, 2009
16. Crowther MA, Ageno W, Schnurr T, Manfredi E, Kinnon K, Garcia D, et al: Oral vitamin K produces a normal INR within 24 hours of its administration in most patients discontinuing warfarin. Haematologica 90:137-139, 2005
17. de Gans K, de Haan RJ, Majoie CB, Koopman MM, Brand A, Dijkgraaf MG, et al: PATCH: platelet transfusion in cerebral haemorrhage: study protocol for a multicentre, randomised, controlled trial. BMC Neurol 10:19, 2010
18. Depta JP, Fowler J, Novak E, Katzan I, Bakdash S, Kottke- Marchant K, et al: Clinical outcomes using a platelet function- guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. Stroke 43:2376-2381, 2012
19. Ducruet AF, Hickman ZL, Zacharia BE, Grobelny BT, DeRosa PA, Landes E, et al: Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. Neurol Res 32:706-710, 2010
20. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation 124:1573-1579, 2011
21. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, et al: Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141:745-752, 2004
22. Ferrari E, Benhamou M, Cerboni P, Marcel B: Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45:456-459, 2005
23. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J: Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 63:1059-1064, 2004
24. Flordal PA, Sahlin S: Use of desmopressin to prevent bleeding complications in patients treated with aspirin. Br J Surg 80:723-724, 1993
25. Foerch C, Sitzer M, Steinmetz H, Neumann-Haefelin T: Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke 37:2165-2167, 2006
26. Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R: Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J Stroke Cerebrovasc Dis 20:227-230, 2011
27. Fukuoka T, Furuya D, Takeda H, Dembo T, Nagoya H, Kato Y, et al: Evaluation of clopidogrel resistance in ischemic stroke patients. Intern Med 50:31-35, 2011
28. Godino C, Mendolicchio L, Figini F, Latib A, Sharp AS, Cosgrave J, et al: Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? Thromb J 7:4, 2009
29. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992, 2011
30. Gratz I, Koehler J, Olsen D, Afshar M, DeCastro N, Spagna PM, et al: The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 104:1417-1422, 1992
31. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow- up of aspirin responder and aspirin non responder. A pilot- study including 180 post-stroke patients. Thromb Res 71: 397-403, 1993
32. Guest JF, Watson HG, Limaye S: Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. Clin Ther 32:2478-2493, 2010
33. Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, et al: Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 37:1465- 1470, 2006
34. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126-2130, 2005
35. Jakubowski JA, Li YG, Small DS, Payne CD, Tomlin ME, Luo J, et al: A comparison of the VerifyNow P2Y12 point-ofcare device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol 56:29-37, 2010
36. Lacut K, Le Gal G, Seizeur R, Prat G, Mottier D, Oger E: Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality. Fundam Clin Pharmacol 21:327-333, 2007
37. Lacut K, van der Maaten J, Le Gal G, Cornily G, Mottier D, Oger E: Antiplatelet drugs and risk of venous thromboembolism: results from the EDITH case-control study. Haematologica 93:1117-1118, 2008
38. Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, et al: Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 106:619-623, 2010
39. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 358:2127-2137, 2008
40. McMillian WD, Rogers FB: Management of prehospital antiplatelet and anticoagulant therapy in traumatic head injury: a review. J Trauma 66:942-950, 2009
41. Mittal MK, Rabinstein AA: Anticoagulation-related intracranial hemorrhages. Curr Atheroscler Rep 14:351-359, 2012
42. Naidech AM, Bendok BR, Garg RK, Bernstein RA, Alberts MJ, Bleck TP, et al: Reduced platelet activity is associated with more intraventricular hemorrhage. Neurosurgery 65: 684-688, 2009
43. Naidech AM, Bernstein RA, Levasseur K, Bassin SL, Bendok BR, Batjer HH, et al: Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol 65:352-356, 2009
44. Naidech AM, Jovanovic B, Liebling S, Garg RK, Bassin SL, Bendok BR, et al: Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke 40:2398-2401, 2009
45. Naidech AM, Liebling SM, Rosenberg NF, Lindholm PF, Bernstein RA, Batjer HH, et al: Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage. Neurocrit Care 16:82-87, 2012
46. Naidech AM, Rosenberg NF, Bernstein RA, Batjer HH: Aspirin use or reduced platelet activity predicts craniotomy after intracerebral hemorrhage. Neurocrit Care 15:442-446, 2011
47. Nishijima DK, Zehtabchi S, Berrong J, Legome E: Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review. J Trauma Acute Care Surg 72:1658-1663, 2012
48. Ozben S, Ozben B, Tanrikulu AM, Ozer F, Ozben T: Aspirin resistance in patients with acute ischemic stroke. J Neurol 258:1979-1986, 2011
49. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H: Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 6:622-631, 2008
50. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, et al: Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 5:1839- 1847, 2007
51. Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, et al: Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 104:287-292, 2010
52. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891, 2011
53. Pleym H, Stenseth R, Wahba A, Bjella L, Tromsdal A, Karevold A, et al: Prophylactic treatment with desmopressin does not reduce postoperative bleeding after coronary surgery in patients treated with aspirin before surgery. Anesth Analg 98:578-584, 2004
54. Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY: Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Adv Ther 29:491-507, 2012
55. Rolfe S, Papadopoulos S, Cabral KP: Controversies of anticoagulation reversal in life-threatening bleeds. J Pharm Pract 23:217-225, 2010
56. Roquer J: Previous antiplatelet treatment and mortality in patients with intracerebral hemorrhage. Stroke 38:863-864, 2007 (Letter)
57. Roquer J, Rodríguez Campello A, Gomis M, Ois A, Puente V, Munteis E: Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. J Neurol 252:412-416, 2005
58. Rossen JD, Chalouhi N, Wassef SN, Thomas J, Abel TJ, Jabbour PM, et al: Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. Clinical article. J Neurosurg 117:929-933, 2012
59. Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen ER, Hillbom M: Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke 37:129-133, 2006
60. Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner SE: Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology 72:1397-1402, 2009
61. Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky A, et al: Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis 25:355-361, 2008
62. Seidel H, Rahman MM, Scharf RE: Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives. Hamostaseologie 31:41-51, 2011
63. Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, et al: Major noncardiac surgery following coronary stenting: when is it safe to operate?. Catheter Cardiovasc Interv 63:141-145, 2004
64. Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, et al: Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8:250-256, 2010
65. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167:1593-1599, 2007
66. Sorimachi T, Fujii Y, Morita K, Tanaka R: Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control. J Neurosurg 106:250-254, 2007
67. Stetler WR, Chaudhary N, Thompson BG, Gemmete JJ, Maher CO, Pandey AS: Prasugrel is effective and safe for neurointerventional procedures. J Neurointerv Surg [epub ahead of print], 2012
68. Taberner DA, Thomson JM, Poller L: Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. BMJ 2:83-85, 1976
69. Thrift AG, McNeil JJ, Forbes A, Donnan GA: Risk of primary intracerebral haemorrhage associated with aspirin and nonsteroidal anti-inflammatory drugs: case-control study. BMJ 318:759-764, 1999
70. Toyoda K, Okada Y, Minematsu K, Kamouchi M, Fujimoto S, Ibayashi S, et al: Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 65:1000- 1004, 2005
71. Tuhrim S: Aspirin-use before ICH: a potentially treatable iatrogenic coagulopathy?. Stroke 37:4-5, 2006
72. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, et al: Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 118:313-320, 2006
73. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al: Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116-1127, 2010
74. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, et al: Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 5:82-90, 2007
75. Watanabe M, Siddiqui FM, Qureshi AI: Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocrit Care 16:203-209, 2012
76. Yasaka M, Oomura M, Ikeno K, Naritomi H, Minematsu K: Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol 82:121-123, 2003
77. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al: Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2 Suppl):e531S-e575S, 2012
78. Yuan ZH, Jiang JK, Huang WD, Pan J, Zhu JY, Wang JZ: A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosci 17:685-693, 2010
79. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al: Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42:3594-3599, 2011